# Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

> clinical trial · VERIFIED · 2026-08-17

Status: NOT_YET_RECRUITING · Sponsor: M.D. Anderson Cancer Center · Condition: Hematological Malignancies

- Company: M.D. Anderson Cancer Center
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07137481

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.